

## References

- Gartoulla P, Worsley R, Bell RJ, Davis SR. *Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years*. *Menopause*. 2015 Jul; 22 (7): 694-701.
- Panay N, Briggs P, Kovacs G. *Managing the menopause: 21<sup>st</sup> century solutions*. Cambridge: Cambridge University Press; 2015. Chapter 26, *Premature ovarian insufficiency: hormonal aspects and long-term health*; 215-222
- Writing Group for the Women's Health Initiative Investigators. *Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial*. *JAMA* 2002 Jul; 288(3): 321–33. Available online at: <http://jama.jamanetwork.com/article.aspx?articleid=195120>
- Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. *The effects of tibolone in older postmenopausal women*. *N Engl J Med* 2008 Aug; 359(7): 697-708. Available online at: <http://www.nejm.org/doi/full/10.1056/NEJMoa0800743#t=article>
- Cirigliano, M. *Bioidentical hormone therapy: a review of the evidence*. *J Womens Health* 2007 Jun; 16(5): 600-31
- Baber RJ, Panay N, Fenton A, IMS Writing Group. *2016 IMS recommendations on women's midlife health and menopause hormone therapy*. *Climacteric*. 2016 Apr; 19(2):109-50. Available online at: <http://dx.doi.org/10.3109/13697137.2015.1129166>
- Panay N. *Body identical hormone replacement*. *Post Reprod Health*. 2014 Jun; 20(2): 69-72.
- Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. *Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis*. *BMJ*. 2008 May; 336(7655): 1227-31
- Cicinelli E. *Intravaginal oestrogen and progestin administration: advantages and disadvantages*. *Best Pract Res Clin Obstet Gynaecol*. 2008 Apr; 22(2): 391-405
- Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. *Testosterone for low libido in menopausal women not taking estrogen therapy*. *N Engl J Med* 2008 Nov; 359: 2005-2017. Available online at: <http://www.nejm.org/doi/full/10.1056/NEJMoa0707302#t=article>
- Braunstein GD. *Safety of testosterone treatment in postmenopausal women*. *Fertil Steril*. 2007 Jul; 88(1): 1-17
- Davis SR, Braunstein GD. *Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women*. *J Sex Med* 2012 Apr; 9(4): 1134–1148.
- Eden, JA. *DHEA replacement for postmenopausal women: placebo or panacea?* *Climacteric*. 2015; 18(4): 439-40
- Labrie F, Martela C, Bérubéa R, Cote I, Labrie C, Cusan L, et al. *Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens*. *J Steroid Biochem Mol Biol*. 2013 Nov; 138: 359-367
- Judd HL, Mebane-Sims I, Legault C, Wasilaukas C, Johnson S, Merino M, et al. *Effects of hormone replacement therapy on endometrial histology in postmenopausal women*. *JAMA*. 1996 Feb; 275(5): 370-5.
- Cuadros JL, Fernandez-Alonso AM, Chedraui P, Cuadros AM, Sabatel RM, Perez-Lopez R. *Metabolic and hormonal parameters in postmenopausal women 10 years after transdermal oestradiol treatment, alone or in combination to micronized oral progesterone*. *Gynae Endocrinol*. 2011 Mar; 27(3): 156-162. Available online at: [https://www.researchgate.net/publication/44628095\\_Metabolic\\_and\\_hormonal\\_parameters\\_in\\_post-menopausal\\_women\\_10\\_years\\_after\\_transdermal\\_oestradiol\\_treatment\\_alone\\_or\\_combined\\_to\\_micronised\\_oral\\_progesterone](https://www.researchgate.net/publication/44628095_Metabolic_and_hormonal_parameters_in_post-menopausal_women_10_years_after_transdermal_oestradiol_treatment_alone_or_combined_to_micronised_oral_progesterone)
- Cicinelli E, de Zigler D, Alfonso R, Nicoletti R, Bellavia M, Colafoglio G. *Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study*. *Fertil Steril*. 2005 Jun; 83(6): 1859-63. Available online at: [http://www.fertstert.org/article/S0015-0282\(05\)00403-6/pdf](http://www.fertstert.org/article/S0015-0282(05)00403-6/pdf)
- Fernandez-Murga L, Hemenegildo C, Tarin JJ, Garcia-Perez MA, Cano A. *Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol*. *Climacteric*. 2012 Oct; 15(5): 455-459.
- Stute P, Neulen J, Wildt L. *The impact of micronized progesterone on the endometrium: a systematic review*. *Climacteric*. 2016 Aug; 19(4): 316-28.
- Casanova G, Spritzer PM. *Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial*. *Lipids Health Dis*. 2012 Dec; 11:133. Available online at: <http://lipidworld.biomedcentral.com/articles/10.1186/1476-511X-11-133>
- Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. *Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort*. In *J Cancer*. 2005 Apr; 114(3): 48-454. Available online at: <http://onlinelibrary.wiley.com/doi/10.1002/ijc.20710/pdf>
- Asi N, Mohammed K, Haydour Q, Gionfriddo MR, Morey Vargas OL, Prokop LJ et al. *Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis*. *Syst Rev*. 2016 Dec; 5:121-9
- Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. *Progestins and progesterone in hormone replacement therapy and the risk of breast cancer*. *J Steroid Biochem Mol Biol*. 2005 Jul; 96(2): 95-108
- Sherif K. *Hormone therapy: A clinical handbook*. New York: Springer; 2013:79-83
- Prior JC, Hitchcock CL. *Progesterone for hot flush and night sweat treatment – effectiveness for severe vasomotor symptoms and lack of withdrawal rebound*. *Gynecol Endocrin*. 2012 Oct; 28(Suppl 2): 7-11